Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 3/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30770772 | 0.97 | CYP3A4 (0.43) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL9803775 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL16192626 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 | |
| Bromide SCHEMBL2831718 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL9803477 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 | |
| Iodide SCHEMBL2831739 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL11017057 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL987207 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL345000 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL196879 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 650 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395442-A1 | TERPOLYMER BASED ON 2,5-BIS(2-THIENYL)THIAZOLO[5,4-D]THIAZOLYL | SOOCHOW UNIVERSITY (CN) | 2021-12-23 | — | — | US | claimed |
| WO-2021120767-A1 | BELT[N]ARENE TROPYLIUM COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 清华大学 | 2021-06-24 | — | — | WO | claimed |
| EP-2705049-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-19 | — | — | EP | claimed |
| US-8957203-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-17 | — | — | US | claimed |
| US-20130115190-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-09 | — | — | US | claimed |
| US-8258314-B2 | Process for the preparation of substituted heteroaromatics | SALTIGO GMBH (US) | 2012-09-04 | — | — | US | claimed |
| EP-2158193-B1 | METHOD FOR THE PRODUCTION OF ALKYL-SUBSTITUTED THIOPHENES | SALTIGO GMBH (DE) | 2012-08-08 | — | — | EP | claimed |
| US-20100217015-A1 | Process for the preparation of substituted heteroaromatics | SALTIGO GMBH (DE) | 2010-08-26 | — | — | US | claimed |
| EP-1541575-B1 | NOVEL PROCESS FOR PRODUCING IMIDAZO(1,2-B)PYRIDAZINE DERIVATIVE | SUMITOMO CHEMICAL CO (JP) | 2010-03-03 | — | — | EP | claimed |
| US-7307165-B2 | Process for producting imidazo[1,2-b]pyridazine derivative | SUMITOMO CHEMICAL TAKEDA AGRO COMPANY, LIMITED (JP) | 2007-12-11 | — | — | US | claimed |
| US-7262264-B2 | Halogenated thiophene monomer for the preparation of regioregular polythiophenes | HONEYWELL INTERNATIONAL INC. (US) | 2007-08-28 | — | — | US | claimed |
| US-20060155105-A1 | Halogenated thiophene monomer for the preparation of regioregular polythiophenes | HONEYWELL INTERNATIONAL INC. | 2006-07-13 | — | — | US | claimed |
| US-20060052620-A1 | Preparation of substituted indenes | BASELL POLYOLEFINE GMBH (DE) | 2006-03-09 | — | — | US | claimed |
| US-20050171108-A1 | Novel process for producting imidazo[1,2-b]pyridazine derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-08-04 | — | — | US | claimed |
| EP-1541575-A1 | NOVEL PROCESS FOR PRODUCING IMIDAZO(1,2-B)PYRIDAZINE DERIVATIVE | Sumitomo Chemical Takeda Agro Company, Limited (JP) | 2005-06-15 | — | — | EP | claimed |
| US-5889184-A | Process for pyrimidinone compounds | PRINCETON UNIVERSITY (US) | 1999-03-30 | — | — | US | claimed |
| US-5753757-A | Electroluminescent polymer compositions and processes thereof | XEROX CORPORATION (US) | 1998-05-19 | — | — | US | claimed |
| JP-7242592-A | — | — | None | — | — | JP | disclosed |
| EP-0303512-A1 | Substituted dibenzocycloheptenimines | MERCK SHARP & DOHME LTD. (GB) | 1989-02-15 | — | — | EP | disclosed |
| EP-0201071-A2 | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1986-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171108-A1 | Novel process for producting imidazo[1,2-b]pyridazine derivative | POR, CBR3, NR2C2 | CYP3A4 49/4885TDP1 4757/4885KDM4E 2179/4885 |
| US-20100217015-A1 | Process for the preparation of substituted heteroaromatics | CBR3, KCNA5, KAT5 | CYP3A4 79/4885TDP1 3427/4885KDM4E 882/4885 |
| US-20060052620-A1 | Preparation of substituted indenes | INTS9, CYP1A2, INF2 | CYP3A4 22/4885TDP1 2898/4885KDM4E 1950/4885 |
| US-20130115190-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, GOT1 | CYP3A4 455/4885TDP1 4097/4885KDM4E 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.